Hepatic Encephalopathy - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/05/15
頁 數：47頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Hepatic Encephalopathy - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Hepatic Encephalopathy - Pipeline Review, H1 2014’, provides an overview of the Hepatic Encephalopathy’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Hepatic Encephalopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatic Encephalopathy and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Hepatic Encephalopathy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hepatic Encephalopathy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hepatic Encephalopathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hepatic Encephalopathy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hepatic Encephalopathy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hepatic Encephalopathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Hepatic Encephalopathy - Pipeline Review, H1 2014’, provides an overview of the Hepatic Encephalopathy’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Hepatic Encephalopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatic Encephalopathy and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Hepatic Encephalopathy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hepatic Encephalopathy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hepatic Encephalopathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hepatic Encephalopathy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hepatic Encephalopathy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hepatic Encephalopathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hepatic Encephalopathy Overview 6
Therapeutics Development 7
Pipeline Products for Hepatic Encephalopathy - Overview 7
Pipeline Products for Hepatic Encephalopathy - Comparative Analysis 8
Hepatic Encephalopathy - Therapeutics under Development by Companies 9
Hepatic Encephalopathy - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Hepatic Encephalopathy - Products under Development by Companies 13
Hepatic Encephalopathy - Companies Involved in Therapeutics Development 14
Ocera Therapeutics, Inc. 14
Hyperion Therapeutics, Inc. 15
Alfa Wassermann S.p.A 16
Umecrine Cognition AB 17
Hepatic Encephalopathy - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 26
rifaximin - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
glycerol phenylbutyrate - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
ornithine phenylacetate - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
THDP-17 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Drugs for Hepatic Encephalopathy - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Hepatic Encephalopathy - Recent Pipeline Updates 34
Hepatic Encephalopathy - Dormant Projects 39
Hepatic Encephalopathy - Product Development Milestones 40
Featured News & Press Releases 40
Feb 25, 2014: Hyperion Therapeutics Announces the Publication of Phase 2 Results of Glycerol Phenylbutyrate for the Treatment of Hepatic Encephalopathy in Hepatology 40
Feb 04, 2014: Salix Pharmaceuticals Announces Issuance Of U. S. Patent For Rifaximin 40
Jan 08, 2014: Ocera Therapeutics Announces Enrollment of the First Patient in a Phase IIb Study for Treatment of Acute Hepatic Encephalopathy 41
Nov 01, 2013: Salix Pharmaceuticals Outlines Data Presentations at American Association for the Study of Liver Diseases Annual Meeting 41
Sep 09, 2013: Scottish Medicines Consortium Accepts TARGAXAN 550 42
May 24, 2013: Norgine Announces PBAC Approval For Xifaxan 550mg In Prevention Of Recurrence Of Hepatic Encephalopathy 43
May 17, 2013: Salix Pharma To Present Data On Rifaximin At Digestive Disease Week 2013 43
May 02, 2013: Hyperion Therapeutics Receives Orphan Drug Exclusivity From FDA 44
Jan 28, 2013: Norgine Pharma And Alfa Wassermann Announce Launch Targaxan 550 In UK 44
Jan 16, 2013: Hyperion Therapeutics Notified By FDA Over Delay In PDUFA Action Date For Ravicti 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 47
Disclaimer 47
List of Tables
Number of Products under Development for Hepatic Encephalopathy, H1 2014 7
Number of Products under Development for Hepatic Encephalopathy - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Late Stage Development, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 11
Comparative Analysis by Early Stage Development, H1 2014 12
Products under Development by Companies, H1 2014 13
Hepatic Encephalopathy - Pipeline by Ocera Therapeutics, Inc., H1 2014 14
Hepatic Encephalopathy - Pipeline by Hyperion Therapeutics, Inc., H1 2014 15
Hepatic Encephalopathy - Pipeline by Alfa Wassermann S.p.A, H1 2014 16
Hepatic Encephalopathy - Pipeline by Umecrine Cognition AB, H1 2014 17
Assessment by Monotherapy Products, H1 2014 18
Number of Products by Stage and Target, H1 2014 20
Number of Products by Stage and Mechanism of Action, H1 2014 22
Number of Products by Stage and Route of Administration, H1 2014 24
Number of Products by Stage and Molecule Type, H1 2014 25
Hepatic Encephalopathy Therapeutics - Recent Pipeline Updates, H1 2014 34
Hepatic Encephalopathy - Dormant Projects, H1 2014 39
List of Figures
Number of Products under Development for Hepatic Encephalopathy, H1 2014 7
Number of Products under Development for Hepatic Encephalopathy - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Early Stage Products, H1 2014 12
Assessment by Monotherapy Products, H1 2014 18
Number of Products by Top 10 Target, H1 2014 19
Number of Products by Stage and Top 10 Target, H1 2014 20
Number of Products by Top 10 Mechanism of Action, H1 2014 21
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 22
Number of Products by Top 10 Route of Administration, H1 2014 23
Number of Products by Stage and Top 10 Route of Administration, H1 2014 24
Number of Products by Stage and Top 10 Molecule Type, H1 2014 25
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hepatic Encephalopathy Overview 6
Therapeutics Development 7
Pipeline Products for Hepatic Encephalopathy - Overview 7
Pipeline Products for Hepatic Encephalopathy - Comparative Analysis 8
Hepatic Encephalopathy - Therapeutics under Development by Companies 9
Hepatic Encephalopathy - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Hepatic Encephalopathy - Products under Development by Companies 13
Hepatic Encephalopathy - Companies Involved in Therapeutics Development 14
Ocera Therapeutics, Inc. 14
Hyperion Therapeutics, Inc. 15
Alfa Wassermann S.p.A 16
Umecrine Cognition AB 17
Hepatic Encephalopathy - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 26
rifaximin - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
glycerol phenylbutyrate - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
ornithine phenylacetate - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
THDP-17 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Drugs for Hepatic Encephalopathy - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Hepatic Encephalopathy - Recent Pipeline Updates 34
Hepatic Encephalopathy - Dormant Projects 39
Hepatic Encephalopathy - Product Development Milestones 40
Featured News & Press Releases 40
Feb 25, 2014: Hyperion Therapeutics Announces the Publication of Phase 2 Results of Glycerol Phenylbutyrate for the Treatment of Hepatic Encephalopathy in Hepatology 40
Feb 04, 2014: Salix Pharmaceuticals Announces Issuance Of U. S. Patent For Rifaximin 40
Jan 08, 2014: Ocera Therapeutics Announces Enrollment of the First Patient in a Phase IIb Study for Treatment of Acute Hepatic Encephalopathy 41
Nov 01, 2013: Salix Pharmaceuticals Outlines Data Presentations at American Association for the Study of Liver Diseases Annual Meeting 41
Sep 09, 2013: Scottish Medicines Consortium Accepts TARGAXAN 550 42
May 24, 2013: Norgine Announces PBAC Approval For Xifaxan 550mg In Prevention Of Recurrence Of Hepatic Encephalopathy 43
May 17, 2013: Salix Pharma To Present Data On Rifaximin At Digestive Disease Week 2013 43
May 02, 2013: Hyperion Therapeutics Receives Orphan Drug Exclusivity From FDA 44
Jan 28, 2013: Norgine Pharma And Alfa Wassermann Announce Launch Targaxan 550 In UK 44
Jan 16, 2013: Hyperion Therapeutics Notified By FDA Over Delay In PDUFA Action Date For Ravicti 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 47
Disclaimer 47
List of Tables
Number of Products under Development for Hepatic Encephalopathy, H1 2014 7
Number of Products under Development for Hepatic Encephalopathy - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Late Stage Development, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 11
Comparative Analysis by Early Stage Development, H1 2014 12
Products under Development by Companies, H1 2014 13
Hepatic Encephalopathy - Pipeline by Ocera Therapeutics, Inc., H1 2014 14
Hepatic Encephalopathy - Pipeline by Hyperion Therapeutics, Inc., H1 2014 15
Hepatic Encephalopathy - Pipeline by Alfa Wassermann S.p.A, H1 2014 16
Hepatic Encephalopathy - Pipeline by Umecrine Cognition AB, H1 2014 17
Assessment by Monotherapy Products, H1 2014 18
Number of Products by Stage and Target, H1 2014 20
Number of Products by Stage and Mechanism of Action, H1 2014 22
Number of Products by Stage and Route of Administration, H1 2014 24
Number of Products by Stage and Molecule Type, H1 2014 25
Hepatic Encephalopathy Therapeutics - Recent Pipeline Updates, H1 2014 34
Hepatic Encephalopathy - Dormant Projects, H1 2014 39
List of Figures
Number of Products under Development for Hepatic Encephalopathy, H1 2014 7
Number of Products under Development for Hepatic Encephalopathy - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Early Stage Products, H1 2014 12
Assessment by Monotherapy Products, H1 2014 18
Number of Products by Top 10 Target, H1 2014 19
Number of Products by Stage and Top 10 Target, H1 2014 20
Number of Products by Top 10 Mechanism of Action, H1 2014 21
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 22
Number of Products by Top 10 Route of Administration, H1 2014 23
Number of Products by Stage and Top 10 Route of Administration, H1 2014 24
Number of Products by Stage and Top 10 Molecule Type, H1 2014 25
